"SensiScreen FFPE and Liquid"
Whereas cancer diagnosis is traditionally performed with immunohistochemistry, genetic stratification is recommended to support prognosis and treatment decisions. The PentaBase SensiScreen portfolio consists of assays intended for solid biopsies (SensiScreen FFPE) for stratification and assays targeting liquid biopsies (SensiScreen Liquid) for monitoring of treatment efficacy, disease progression and relapse.
The session will cover:
- an introduction to the clinical settings where genetic stratification is recommended with reference to hospital laboratory flow and clinical guidelines and
- introduction to the benefits of liquid biopsy based analysis of treatment efficiency, disease progression and relapse,
- design and technical performance of SensiScreen assays,
- SensiScreen technical cut-offs and read-out and 5) the SensiScreen competitive landscape and unique selling points.
